Dipna Pharmachem FY26 PAT jumps 170% to Rs 2.63 cr, ops cash flow negative

Pat Growth 25pctNegative Operating CashflowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹6.00

prior close

₹6.06

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+0.3% vs market

Pharmaceuticals peers, median of 165sector+0.2%-0.2% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+3.1

15m

+3.1

30m

+2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0-0.3+0.3+0.2-0.2

Next day

+0.0-0.1+0.1-0.3+0.3

-4.5-0.8-3.7-0.5-4.0

-6.3-2.8-3.5-1.2-5.1

+5.0-1.0+6.0-0.7+5.7

-3.2+0.4-3.6-0.1-3.1

-7.2-0.5-6.7+0.6-7.8

15d

-16.0-1.9-14.1-1.8-14.2

-17.8+0.4-18.3-0.5-17.3

-3.3+3.5-6.8+0.9-4.3

-28.7+2.0-30.7+0.4-29.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dipna Pharmachem reported FY26 revenue of Rs 12,908 lakhs (up 3.3% YoY) and net profit of Rs 263 lakhs (up 170% from Rs 97 lakhs). EPS rose to Rs 1.00 from Rs 0.41. However, operating cash flow was deeply negative at Rs 1,832 lakhs versus negative Rs 919 lakhs last year. Q4 revenue was weak at Rs 202 lakhs. Board also confirmed no deviation in use of preferential warrant funds raised for working capital and general corporate purposes. Auditor issued unmodified opinion.

Likely market impact

Strong profit growth, but deeply negative operating cash flow signals working capital strain. No fund use deviation is a positive.